Clinical Trials Logo

Stage IV Prostate Cancer clinical trials

View clinical trials related to Stage IV Prostate Cancer.

Filter by:

NCT ID: NCT05189457 Recruiting - Prostate Cancer Clinical Trials

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therapy with docetaxel and LHRH analog would improve the outcome of high risk metastatic/stage IV prostate cancer.

NCT ID: NCT05025748 Completed - Clinical trials for Stage IV Breast Cancer

Ask Questions (ASQ):Implementation of a Communication Intervention

Start date: August 25, 2021
Phase: N/A
Study type: Interventional

This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.

NCT ID: NCT04267575 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

Start date: July 30, 2019
Phase: N/A
Study type: Interventional

The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.

NCT ID: NCT04113096 Recruiting - Clinical trials for Stage IV Breast Cancer

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Start date: October 1, 2018
Phase: Early Phase 1
Study type: Interventional

This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

NCT ID: NCT03880422 Recruiting - Obesity Clinical Trials

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

Start date: April 4, 2019
Phase: N/A
Study type: Interventional

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.

NCT ID: NCT03827473 Terminated - Clinical trials for Stage IV Prostate Cancer

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

ACADEMIC
Start date: February 8, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well docetaxel or abiraterone acetate work when combined with androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and abiraterone acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Antihormone therapy, such as ADT may lessen the amount of androgen made by the body. It is not yet known whether docetaxel or abiraterone acetate work better when combined with ADT in treating patients with hormone sensitive prostate cancer.

NCT ID: NCT03805594 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 10, 2019
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating patients with castration-resistant prostate cancer that has spread to other places in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating prostate cancer.

NCT ID: NCT03707184 Completed - Clinical trials for Stage IV Prostate Cancer

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

Start date: October 2, 2018
Phase: Phase 2
Study type: Interventional

This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth. PET/CT uses x-rays to take pictures inside the body. Comparing results of fluciclovine 18F PET/CT imaging may help doctors predict a patient's response to treatment and help plan the best treatment.

NCT ID: NCT03596710 Withdrawn - Clinical trials for Stage IV Prostate Cancer

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Start date: June 14, 2018
Phase: N/A
Study type: Interventional

This trial studies image-guided biopsies work in identifying mechanisms of resistance in participants with castration resistant prostate cancer that has spread to other places in the body and who are undergoing radioligand therapy (RLT). Tissue sample collected from a biopsy may help determine why response to RLT varies among patients, and this may help researchers to find better treatments for advanced prostate cancer.

NCT ID: NCT03511196 Active, not recruiting - Prostate Cancer Clinical Trials

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Start date: September 17, 2018
Phase: Early Phase 1
Study type: Interventional

Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).